4.5 Article

EUROPEAN CONSENSUS TABLE ON THE USE OF BOTULINUM TOXIN TYPE A IN ADULT SPASTICITY

期刊

JOURNAL OF REHABILITATION MEDICINE
卷 41, 期 1, 页码 13-25

出版社

FOUNDATION REHABILITATION INFORMATION
DOI: 10.2340/16501977-0303

关键词

botulinum toxin; upper motor neurone syndrome; adult spasticity; acquired brain injury

资金

  1. Allergan
  2. Ipsen
  3. Merz
  4. Elan
  5. Medtronic
  6. Novartis
  7. Boehringer

向作者/读者索取更多资源

A group of clinicians from across Europe experienced in the use of botulinum toxin type a for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. this consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据